Literature DB >> 27428884

Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach.

Rachel G Greenberg1, Chiara Melloni, Huali Wu, Daniel Gonzalez, Lawrence Ku, Kevin D Hill, Christoph P Hornik, Michael Cohen-Wolkowiez, Jeffrey T Guptill.   

Abstract

OBJECTIVES: Our study aimed to determine whether data obtained from the medical literature can be used to estimate the therapeutic index of 5 antiepileptic drugs (AEDs): carbamazepine, lamotrigine, phenobarbital, phenytoin, and valproate.
METHODS: We performed a literature search using PubMed and EMBASE to collect published safety, efficacy, and therapeutic monitoring data for 5 AEDs and extracted all relevant information into a drug- and study-specific drug database. For each AED, we summarized (1) type, severity, and incidence of toxicity-related adverse events and toxicity-associated range of drug doses or concentrations; (2) effective versus toxic concentration and dose (therapeutic range); and (3) therapeutic drug monitoring practices. We defined therapeutic index as the ratio of the minimum toxic concentration to the minimum effective concentration.
RESULTS: We reviewed a total of 810 full-text articles and extracted data from 163. The literature suggests that the therapeutic index of phenytoin is 2. The therapeutic indices of phenobarbital and valproate exceed 2. There were insufficient data to precisely quantify the therapeutic indices of carbamazepine and lamotrigine.
CONCLUSIONS: For some drugs, this approach offers a low-cost method of therapeutic index estimation. Our results can serve as preliminary data for future trials and as guidance for US Food and Drug Administration decision making regarding narrow therapeutic index classification.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27428884      PMCID: PMC5026556          DOI: 10.1097/WNF.0000000000000172

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.379


  74 in total

1.  Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin.

Authors:  F BUCHTHAL; O SVENSMARK; P J SCHILLER
Journal:  Arch Neurol       Date:  1960-06

Review 2.  What are narrow therapeutic index drugs?

Authors:  G Levy
Journal:  Clin Pharmacol Ther       Date:  1998-05       Impact factor: 6.875

3.  Serum levels of sodium valproate, phenytoin and carbamazepine and seizure control in epilepsy.

Authors:  T Goggin; C Casey; N Callaghan
Journal:  Ir Med J       Date:  1986-06

4.  A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy.

Authors:  G Jannuzzi; P Cian; C Fattore; G Gatti; A Bartoli; F Monaco; E Perucca
Journal:  Epilepsia       Date:  2000-02       Impact factor: 5.864

5.  Safety and tolerance of rapidly infused Depacon. A randomized trial in subjects with epilepsy.

Authors:  R E Ramsay; D Cantrell; S D Collins; J K Walch; D K Naritoku; J C Cloyd; K Sommerville
Journal:  Epilepsy Res       Date:  2003-01       Impact factor: 3.045

6.  Clorazepate and phenobarbital as antiepileptic drugs: a double-blind study.

Authors:  A J Wilensky; L M Ojemann; N R Temkin; A S Troupin; C B Dodrill
Journal:  Neurology       Date:  1981-10       Impact factor: 9.910

7.  Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study.

Authors:  F Matsuo; P Gay; J Madsen; K G Tolman; D E Rollins; M E Risner; A A Lai
Journal:  Epilepsia       Date:  1996-09       Impact factor: 5.864

8.  Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects.

Authors:  S R Bareggi; M R Tata; A Guizzaro; R Pirola; A Parisi; C G Monza
Journal:  Int Clin Psychopharmacol       Date:  1994       Impact factor: 1.659

9.  Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin.

Authors:  D M Shaner; S A McCurdy; M O Herring; A J Gabor
Journal:  Neurology       Date:  1988-02       Impact factor: 9.910

10.  A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group.

Authors:  R H Mattson; J A Cramer; J F Collins
Journal:  N Engl J Med       Date:  1992-09-10       Impact factor: 91.245

View more
  11 in total

Review 1.  Biological barriers, and the influence of protein binding on the passage of drugs across them.

Authors:  Karolina Wanat
Journal:  Mol Biol Rep       Date:  2020-03-05       Impact factor: 2.316

Review 2.  Nano optical and electrochemical sensors and biosensors for detection of narrow therapeutic index drugs.

Authors:  Omid Heydari Shayesteh; Reza Mahjub; Akram Ranjbar; Katayoun Derakhshandeh; Mahdi Jamshidi
Journal:  Mikrochim Acta       Date:  2021-11-06       Impact factor: 5.833

3.  NIR Spectroscopy as an Online PAT Tool for a Narrow Therapeutic Index Drug: Toward a Platform Approach Across Lab and Pilot Scales for Development of a Powder Blending Monitoring Method and Endpoint Determination.

Authors:  Sameer Talwar; Pallavi Pawar; Huiquan Wu; Koushik Sowrirajan; Suyang Wu; Benoît Igne; Richard Friedman; Fernando J Muzzio; James K Drennen
Journal:  AAPS J       Date:  2022-09-28       Impact factor: 3.603

Review 4.  Therapeutic Basis of Generic Substitution of Antiseizure Medications.

Authors:  Sarah Elmer; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2022-03-03       Impact factor: 4.402

5.  Impact of antiepileptic-drug treatment burden on health-care-resource utilization and costs.

Authors:  Krithika Rajagopalan; Sean D Candrilli; Mayank Ajmera
Journal:  Clinicoecon Outcomes Res       Date:  2018-10-16

6.  Improving antibacterial prescribing safety in the management of COPD exacerbations: systematic review of observational and clinical studies on potential drug interactions associated with frequently prescribed antibacterials among COPD patients.

Authors:  Yuanyuan Wang; Muh Akbar Bahar; Anouk M E Jansen; Janwillem W H Kocks; Jan-Willem C Alffenaar; Eelko Hak; Bob Wilffert; Sander D Borgsteede
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

Review 7.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update.

Authors:  Jason H Karnes; Allan E Rettie; Andrew A Somogyi; Rachel Huddart; Alison E Fohner; Christine M Formea; Ming Ta Michael Lee; Adrian Llerena; Michelle Whirl-Carrillo; Teri E Klein; Elizabeth J Phillips; Scott Mintzer; Andrea Gaedigk; Kelly E Caudle; John T Callaghan
Journal:  Clin Pharmacol Ther       Date:  2020-09-06       Impact factor: 6.875

8.  A Novel Correction Equation Avoids High-Magnitude Errors in Interpreting Therapeutic Drug Monitoring of Phenytoin Among Critically Ill Patients.

Authors:  Megan E Barra; Kristy M Phillips; David Y Chung; Eric S Rosenthal
Journal:  Ther Drug Monit       Date:  2020-08       Impact factor: 3.118

9.  Incidence and Prevalence of Antiepileptic Medication Use in Community-Dwelling Persons with and without Alzheimer's Disease.

Authors:  Tatyana Sarycheva; Heidi Taipale; Piia Lavikainen; Jari Tiihonen; Antti Tanskanen; Sirpa Hartikainen; Anna-Maija Tolppanen
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  On-Site Biolayer Interferometry-Based Biosensing of Carbamazepine in Whole Blood of Epileptic Patients.

Authors:  Sumin Bian; Ying Tao; Zhoule Zhu; Peixi Zhu; Qiqin Wang; Hemmings Wu; Mohamad Sawan
Journal:  Biosensors (Basel)       Date:  2021-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.